Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Rheopheresis for Dry Age-Related Macular Degeneration (AMD ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
oNet Registry Update March 2005<br />
dverse Events / Side Effects (AE) and Vascular Access Problems (VAP<br />
%<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
Patients with <strong>AMD</strong>, all age groups<br />
n = 3618 protocols<br />
5,4 6,2<br />
2,0 1,8<br />
0,6<br />
Class I Class II Class III<br />
Adverse events / side effects Vascular access problems<br />
0,9<br />
All class III events<br />
(AE/SE + VAP, 1.49% of treatments)<br />
Dizziness/<br />
lightheaded<br />
0.03%<br />
Chilling<br />
0.08%<br />
Fever<br />
0.03%<br />
Vascular<br />
access<br />
problem<br />
0.88%<br />
Hemolysis/ blood<br />
in plasma circuit<br />
0.14%<br />
Hypotension<br />
0.30%<br />
Nausea/<br />
vomitting<br />
0.03%
Change language